NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Elanco Animal Health Incorporated (ELAN) Stock Analysis

Elanco Animal Health Incorporated (ELAN) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

ELAN

$22.55

−$0.15 (−0.66%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ELAN with… →

ELAN Key Statistics

As of Oct 21, 2026
Trading
Open
$22.98
Previous Close
$22.70
Day's Range
22.23–22.76
52-Week Range
19.40–27.98
Volume
4.86M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.71
Valuation
Market Cap
$11.26B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
17.53
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
4.04
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.41
Financials (FY)
Revenue (FY)
$4.72B+6.22%
Net Income (FY)
−$232.00M−168.64%
Profit marginThe share of revenue left as profit after all costs and taxes.
−3.96%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
499.45M
1-Year Return
+4.30%
Dividend and dates
Earnings Date
November 6, 2026
Avg Volume
6.27M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ELAN closed at $22.55, +4.30% over 1 year.

Elanco Animal Health Incorporated (ELAN) has a market capitalization of $11.26B.

In fiscal 2025, ELAN reported revenue of $4.72B.

ELAN Stock Return by Calendar Year

Elanco Animal Health Incorporated (ELAN) return since Sep 2018: what $10,000 became

1 year
$10,000 $10,430
+4.30%
5 years
$10,000 $6,711
−32.89%
Since Sep 2018
$10,000 $6,264
−37.36%

If you had invested $10,000 in Elanco Animal Health Incorporated (ELAN) at the close on September 20, 2018, the earliest close on record here, it would have been worth $6,264 at the close on October 21, 2026: −37.36% in total, −5.62% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−0.35%
2025+86.87%
2024−18.72%
2023+21.93%
2022−56.94%
2021−7.47%
2020+4.14%
2019−6.60%
2018 (partial year)−12.42%

As of October 21, 2026.

ELAN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.72B−$232.00M−4.9%
2024$4.44B$338.00M7.6%
2023$4.42B−$1.23B−27.9%
2022$4.41B−$78.00M−1.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.72B$2.59B$252.00M−$232.00M−4.9%
2024$4.44B$2.44B$251.00M$338.00M7.6%
2023$4.42B$2.49B$326.00M−$1.23B−27.9%
2022$4.41B$2.50B$384.00M−$78.00M−1.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ELAN Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricELANDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.242.107% above
Profit margin−3.96%−8.14%4.2 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Elanco Animal Health Incorporated (ELAN) carries a market capitalisation of $11.26B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 9,400.

The 52-week range on file runs from $19.40 to $27.98. The most recent close on file for ELAN is $22.55, dated October 21, 2026. That is −$0.15 (−0.66%) against the previous close. The latest close sits 16.24% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $4.72B. That is +6.22% against the prior fiscal year, when revenue was $4.44B. The same year closed with a net loss of $232.00M. The reported profit margin is −3.96%. That is 4.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −0.41.

Across the 4 fiscal years on file, revenue moves from $4.41B in 2022 to $4.72B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 17.53. The PEG ratio, which sets the P/E against expected earnings growth, reads 4.04. The price-to-sales ratio is 2.24. On price-to-sales that is 6.84% above the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year total return is +4.30%. Measured over 5 years, that is −7.67% a year compounded. Beta against the wider market is reported at 1.71. Annualized volatility over the trailing 8 years is 43.99%.

Growth & Income

No dividend is on file for ELAN.

Across the complete calendar years on file, 2025 returned +86.87% and 2022 returned −56.94%. Of the 7 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −0.35%.

Peer Comparison

Elanco Animal Health Incorporated (ELAN) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Elanco Animal Health Incorporated ELAN $11.26B —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Elanco Animal Health Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Visit website →